Genentech denies US specialists of Avastin

Article

Genentech is seeking to restrict the use of its anti-VEGF drug Avastin by ophthalmologists in the US.

Genentech is seeking to restrict the use of its anti-VEGF drug Avastin by ophthalmologists in the US.

Avastin is currently approved as an anti-cancer treatment, however, ophthalmologists have been using the agent off-label for the treatment of age-related macular degeneration (AMD).

The move is not proving popular with some doctors, who say it may force them to use Genentech's much more expensive drug, Lucentis. Lucentis costs approximately $2,000 a dose, while Avastin costs just $50 a dose.

In a letter to retina specialists, Genentech said that, as of November 30, 2007, its wholesalers would no longer provide Avastin to compounding pharmacies — companies that can divide a vial of Avastin into smaller portions for use in the eye.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.